Two of the world’s leading organizations for restoring sight, Advancing Sight Network (ASN) and Miracles In Sight (MIS), have announced a merger that will take effect on January 1, 2026. The unified organization aims to advance the science and practice of vision restoration through expanded research, innovation, and global collaboration. More than 253 million people worldwide live with blindness or moderate to severe visual impairment. ASN and MIS have spent decades addressing this challenge through pioneering advancements in corneal transplantation, tissue recovery, and ocular research.
“For decades, both of our organizations have been guided by the same calling: restoring sight, offering hope to patients and families, stewarding the gift of donation and equipping healthcare frontliners,” said Alan Blake, executive officer of Advancing Sight Network. “Though our paths began separately, our missions have always pointed in the same direction. Today, we have the opportunity to bring those paths together.”
“This is a true merger of equals: two partners uniting to expand what’s possible—not just in eye banking, but in holistic vision care and innovation,” said Ingrid Schunder, president & chief executive officer of Miracles In Sight. “We believe that by joining forces, we can accomplish more than either of us could alone. Our combined strengths, from innovative research and clinical initiatives to international reach, position us to be a top-tier leader in eye care in the United States and beyond.”
The merged organization will advance its mission through:
- Broadened research capacity: Expansion into clinical trials, cellular therapeutics, and novel approaches for treating noncorneal causes of blindness.
- Scalable infrastructure: Increased operational and financial capacity to support innovation and long-term sustainability.
- Collaborative leadership: Strengthening partnerships with ophthalmologists, researchers, and health care systems to accelerate translation from lab to clinic.
- Commitment to innovation: Driving the next generation of ocular therapies to ensure the mission of restoring sight continues for generations to come.
